Objective  To observe the clinical efficacy of moxifloxacin in the treatment of senile patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

  Methods  Totally 130 senile patients with AECOPD were randomly divided into study group and control group, with 65 cases in each group. The control group was treated with cefoperazone/sulbactam and routine therapy, while the study group was treated with moxifloxacin and routine therapy. Indexes such as percentage of forced expiratory volume in the first second in predict value (FEV ₁%), maximum ventilation (MVV), ratio of forced expiratory volume in the first second to forced vital capacity (FEV₁/FVC), serum glutathione peroxidase (GPx), superoxide dismutase (SOD), nitric oxide (NO), malondialdehyde (MDA), endothelin (ET-1), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-8(IL-8), tumor necrosis factor-α (TNF-α), procalcitonin (PCT) and C-reactive protein (CRP) before and after treatment were compared between two groups.

  Results  After treatment, the levels of FEV₁%, MVV, FEV₁/FVC, SOD, GPx and NO in the study group were significantly higher than those in the control group, while the levels of MDA, ET-1, sICAM-1, IL-8, TNF-α, PCT and CRP were significantly lower than those in the control group (P < 0.05).

  Conclusion  Moxifloxacin has a better anti-infection efficacy in treating senile patients with AECOPD, which can reduce the inflammatory reaction and vascular endothelial injury, and enhance anti-oxidant function.